Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

DelveInsight Evaluates a Robust Waldenstrom’s Macroglobulinemia Pipeline as 20+ Influential Pharma Players to Set Foot in the Domain

Published

on

<!– Name:DistributionId Value:8823668 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:3ce4fe72-91b5-4c53-82e6-f34c0c06414c –>

New York, USA, April 24, 2023 (GLOBE NEWSWIRE) — DelveInsight Evaluates a Robust Waldenstrom’s Macroglobulinemia Pipeline as 20+ Influential Pharma Players to Set Foot in the Domain

The prevalence of Waldenstrom’s Macroglobulinemia has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Waldenstrom’s Macroglobulinemia and the growing research and development activities to develop novel therapies to treat Waldenstrom’s Macroglobulinemia to drive the market. The companies developing the potential therapies in the last stage of development include Amgen, Abbvie, Roche, Bristol-Myers Squibb, and several others.

DelveInsight’s Waldenstrom’s Macroglobulinemia Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Waldenstrom’s macroglobulinemia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the waldenstrom’s macroglobulinemia pipeline domain.

Key Takeaways from the Waldenstrom’s Macroglobulinemia Pipeline Report

  • DelveInsight’s Waldenstrom’s macroglobulinemia pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Waldenstrom’s macroglobulinemia treatment. 
  • Key Waldenstrom’s macroglobulinemia companies such as Amgen, Abbvie, Roche, Bristol-Myers Squibb, X4 Pharmaceuticals, TransThera Sciences, BeiGene, Janssen, Ascentage Pharma, Gilead Sciences, ADC Therapeutics, InnoCare Pharma, Mustang Bio, and others are evaluating new Waldenstrom’s macroglobulinemia drugs to improve the treatment landscape.
  • Promising Waldenstrom’s macroglobulinemia pipeline therapies such as Carfilzomib, ABT199, Obinutuzumab, Dasatinib, Mavorixafor, TT-01488, BGB 16673, Zydelig, Daratumumab, APG-2575, loncastuximab tesirine, Orelabrutinib, MB-106, and others are under different phases of waldenstrom’s macroglobulinemia clinical trials.
  • In November 2022, Loxo@Lilly announced that study investigators will present data from the BRUIN Phase I/II trial of pirtobrutinib at the American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2022, in New Orleans, Louisiana, and virtually. Pirtobrutinib is an investigational, highly selective, potent, reversible inhibitor of Bruton’s tyrosine kinase (BTK). The pirtobrutinib oral and poster presentations will provide updated clinical data from the ongoing BRUIN Phase I/II study in previously treated chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Richter transformation, and Waldenström macroglobulinemia. 
  • In October 2022, Mustang Bio announced that results from the Waldenstrom macroglobulinemia (“WM”) cohort and other interim data from the ongoing Phase I/II clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy being conducted at Fred Hutchinson Cancer Center (“Fred Hutch”), will be presented at the 11th International Workshop for Waldenstrom’s Macroglobulinemia (“IWWM-11”) taking place in Madrid, Spain.
  • In June 2022, The FDA granted orphan drug designation to MB-106, for the treatment of patients with Waldenstrom macroglobulinemia (WM).
  • In August 2021, Cellectar Biosciences announced that it had entered into a commercial manufacturing and supply agreement with Evergreen Theragnostics. The agreement with Evergreen provides long-term commercial supply of iopofosine I-131 and supply of clinical study material for Cellectar’s pivotal study in Waldenstrom’s macroglobulinemia (WM) as well as ongoing Phase I and Phase II clinical studies.

Request a sample and discover the recent advances in Waldenstrom’s macroglobulinemia treatment drugs @ Waldenstrom’s Macroglobulinemia Pipeline Report

The Waldenstrom’s macroglobulinemia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage waldenstrom’s macroglobulinemia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the waldenstrom’s macroglobulinemia clinical trial landscape.

Waldenstrom’s Macroglobulinemia Overview

Waldenstrom’s macroglobulinemia is a rare cancer that starts in white blood cells. The bone marrow overproduces white blood cells, crowding out normal healthy blood cells. Waldenstrom macroglobulinemia is a form of non-Hodgkin lymphoma. It is also known as lymphoplasmacytic lymphoma. Waldenstrom macroglobulinemia is a slow-growing disease that may not manifest for many years. Waldenstrom’s macroglobulinemia symptoms may include easy bruising, fatigue, weight loss, fever, numbness in hands and feet, vision changes, and shortness of breath. It is still unknown what causes Waldenstrom’s macroglobulinemia. The disease usually begins with a single abnormal white blood cell that develops errors (mutations) in its genetic code. Chemotherapy, plasma exchange, targeted therapy, biological therapy, and bone marrow transplant are all possible Waldenstrom’s macroglobulinemia treatments.

Find out more about Waldenstrom’s macroglobulinemia treatment drugs @ Drugs for Waldenstrom’s Macroglobulinemia Treatment

A snapshot of the Waldenstrom’s Macroglobulinemia Pipeline Drugs mentioned in the report:

Drugs Company Phase  MoA RoA
APG-2575 Ascentage Pharma Phase II Proto-oncogene protein c-bcl-2 inhibitor Oral 
Obinutuzumab Roche Phase II Antibody-dependent cell cytotoxicity; Cell death stimulants Intravenous
ABT199 Abbvie Phase II Proto-oncogene protein c-bcl-2 inhibitors Oral 
Dasatinib  Bristol-Myers Squibb Phase I Bcr-abl tyrosine kinase inhibitors; EphA2 receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Src-Family kinase inhibitors Oral 
Mavorixafor  Sanofi/X4 Pharmaceuticals Phase I CXCR4 receptor antagonists Oral
TT-01488 TransThera Biosciences Phase I Agammaglobulinaemia tyrosine kinase inhibitors Oral

Learn more about the emerging waldenstrom’s macroglobulinemia pipeline therapies @ Waldenstrom’s Macroglobulinemia Clinical Trials

Waldenstrom’s Macroglobulinemia Therapeutics Assessment

The Waldenstrom’s macroglobulinemia pipeline report proffers an integral view of the waldenstrom’s macroglobulinemia emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Waldenstrom’s Macroglobulinemia Pipeline Report 

  • Coverage: Global 
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Oral, Subcutaneous, Intravenous, Intramuscular
  • Therapeutics Assessment By Molecule Type: Bispecific Antibody, Peptides, Small molecule, Gene therapy
  • Therapeutics Assessment By Mechanism of Action: Apoptosis stimulants, Proto-oncogene protein c-bcl-2 inhibitors, Proteasome inhibitors, Bcr-abl tyrosine kinase inhibitors, EphA2 receptor antagonists, Platelet-derived growth factor beta receptor antagonists, Proto oncogene protein c-kit inhibitors, Src-Family kinase inhibitors, CXCR4 receptor antagonists, Agammaglobulinaemia tyrosine kinase inhibitors
  • Key Waldenstrom’s Macroglobulinemia Companies: Amgen, Abbvie, Roche, Bristol-Myers Squibb, X4 Pharmaceuticals, TransThera Sciences, BeiGene, Janssen, Ascentage Pharma, Gilead Sciences, ADC Therapeutics, InnoCare Pharma, Mustang Bio, and others
  • Key Waldenstrom’s Macroglobulinemia Pipeline Therapies: Carfilzomib, ABT199, Obinutuzumab, Dasatinib, Mavorixafor, TT-01488, BGB 16673, Zydelig, Daratumumab, APG-2575, loncastuximab tesirine, Orelabrutinib, MB-106, and others

Dive deep into rich insights for new drugs for Waldenstrom’s macroglobulinemia treatment, visit @ Waldenstrom’s Macroglobulinemia Drugs

Table of Contents

1. Waldenstrom’s Macroglobulinemia Pipeline Report Introduction
2. Waldenstrom’s Macroglobulinemia Pipeline Report Executive Summary
3. Waldenstrom’s Macroglobulinemia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Waldenstrom’s Macroglobulinemia Clinical Trial Therapeutics
6. Waldenstrom’s Macroglobulinemia Pipeline: Late Stage Products (Pre-registration)
7. Waldenstrom’s Macroglobulinemia Pipeline: Late Stage Products (Phase III)
8. Waldenstrom’s Macroglobulinemia Pipeline: Mid Stage Products (Phase II)
9. Waldenstrom’s Macroglobulinemia Pipeline: Early Stage Products (Phase I)
10. Waldenstrom’s Macroglobulinemia Pipeline Therapeutics Assessment
11. Inactive Products in the Waldenstrom’s Macroglobulinemia Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Waldenstrom’s Macroglobulinemia Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the waldenstrom’s macroglobulinemia pipeline therapeutics, reach out @ Waldenstrom’s Macroglobulinemia Treatment Drugs

Related Reports

Waldenstrom’s Macroglobulinemia Epidemiology

Waldenstrom’s Macroglobulinemia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the waldenstrom’s macroglobulinemia epidemiology trends.

Waldenstrom’s Macroglobulinemia Market

Waldenstrom’s Macroglobulinemia Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key waldenstrom’s macroglobulinemia companies, including Roche, Bristol-Myers Squibb, Mavorixafor, TransThera Sciences, among others.

Multiple Myeloma Market

Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others.

Multiple Myeloma Pipeline

Multiple Myeloma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others.

Relapsing Refractory Multiple Myeloma Pipeline

Relapsing Refractory Multiple Myeloma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key relapsing refractory multiple myeloma companies, including AbbVie, Amgen, Takeda Oncology, among others.

Refractory Multiple Myeloma Market

Refractory Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key refractory multiple myeloma companies, including Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market 

Related Healthcare Blogs 

Multiple Myeloma Treatment Market 

Upcoming Oncology Drugs

Oncology Market Outlook

Future of Oncology Market

Related Cases Studies

Competitive Intelligence

Market Assessment

Product Assessment

Epidemiology Assessment

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn 


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Latest VIPRE Security Group Email Threat Trends Research Exposes Global Phishing and Malware Threat Landscape

Published

on

latest-vipre-security-group-email-threat-trends-research-exposes-global-phishing-and-malware-threat-landscape

The US, UK, Ireland, and Japan emerge as the main source of spam; manufacturing, government, and IT sectors are most victimized; Pikabot top malware family 
LONDON, May 9, 2024 /PRNewswire/ — VIPRE Security Group, a global leader and award-winning cybersecurity, privacy, and data protection company, today released its Q1 2024 Email Threat Trends report, based on an analysis of 1.8 billion emails. The findings reveal the evolving landscape of email-based threats and emerging tactics malicious actors are employing.

The US, UK, Ireland, and Japan top the spam sources listThe report identifies the US as the top source of spam emails globally, followed by the U.K., Ireland, and Japan. The US, UK, and Canada are the top three countries most subjected to email-based attacks.
Attackers aim at the manufacturing sectorThe manufacturing, government, and IT sectors are the most victimized by malicious actors. In Q1 2024, the manufacturing sector suffered 43% of email-based attacks, with the government (15%) and IT (11%) trailing well behind. This is a change from Q1 2023, when attackers targeted the financial (25%), healthcare (22%), and education (15%) sectors most often.
Scams surpassing phishing This research warns that ‘scams’ within the spam category are growing in popularity among cybercriminals, overtaking phishing emails in the first quarter of 2024.
There’s been a notable increase in phishing emails masquerading as communications from Human Resources, falsely claiming to relate to employee benefits, compensation, or insurance within a company. These emails contain malicious attachments in .html or .pdf formats, featuring phishing QR codes that redirect recipients to phishing sites upon scanning.
New phishing trends and techniquesIn email phishing campaigns, 75% of emails leverage links, 24% favor attachments, and 1% use QR codes. Attackers are employing links in phishing emails for URL redirection (54%), compromised websites (22%), and newly created domains (15%).
Emerging tactics employed by cybercriminals to execute phishing attacks include the use of .ics calendar invite and .rtf attachment file formats to trick recipients into opening malicious content.
Malspam links and top malware familyEncouraged by the success of password-oriented phishing emails that use links, cybercriminals are opting for malicious links in malspam emails instead of attachments. Malware is increasingly being hidden in cloud storage platforms such as Google Drive. The use of malware-based emails employing attachments has increased to 22% in Q1 2024, from only 3% in Q1 2023.
Due to the void left by the dismantled Qakbot malware, Pikabot has emerged as the top malware family, with IceID a distant second.
Exploiting software vulnerabilitiesCriminals are exploiting a web application vulnerability, most notably Reflected Cross-Site Scripting (XSS), focusing on the tag attribute “href”, to circumvent detection by using a variety of tactics such as images as the entire email content, encoding URLs, and directing the victim through multiple URLs.
Malicious actors are also finding success with thread hijacking of NTLM (NT LAN Manager), a security protocol used by Microsoft Windows operating systems for authentication. By hijacking the authentication thread, attackers extract NTLM challenge-response hashes from legitimate SMB (Server Message Block) sessions, to enable them to impersonate authenticated users and gain unauthorized access.
“Criminals are using email with success to scam, infiltrate networks, and unleash malicious payloads,” warns Usman Choudhary, Chief Product and Technology Officer, VIPRE Security Group. “We’re witnessing bad actors relentlessly exploiting human vulnerabilities and software flaws, circumventing email gateways and security measures with alarming precision. Robust email and endpoint defenses, coupled with a vigilant human frontline, remain our strongest defense against these unyielding attacks.”
To read the full report, click here: VIPRE’s Email Threat Trends Report: Q1 2024.
VIPRE leverages its unique understanding of email security to equip organizations with the information they need to protect themselves. This report is based on proprietary intelligence gleaned from round-the-clock vigilance of the cybersecurity landscape.
About VIPRE Security Group VIPRE Security Group, part of Ziff Davis, Inc., is a leading provider of internet security solutions purpose-built to protect businesses, solution providers, and home users from costly and malicious cyber threats. With over 25 years of industry expertise, VIPRE is one of the world’s largest threat intelligence clouds, delivering exceptional protection against today’s most aggressive online threats. Our award-winning software portfolio includes next-generation antivirus endpoint cloud solutions, advanced email security products, along with threat intelligence for real-time malware analysis, and security awareness training for compliance and risk management. VIPRE solutions deliver easy-to-use, comprehensive layered defense through cloud-based and server security, with mobile interfaces that enable instant threat response. VIPRE is a proud Advanced Technology Partner of Amazon Web Services operating globally across North America and Europe.
The group operates under various brands, including VIPRE®, StrongVPN®, IPVanish®, Inspired eLearning®, Livedrive®, and SugarSync®. www.VIPRE.com

View original content:https://www.prnewswire.co.uk/news-releases/latest-vipre-security-group-email-threat-trends-research-exposes-global-phishing-and-malware-threat-landscape-302141052.html

Continue Reading

Artificial Intelligence

Logicalis unites Australia and Asia operations as Logicalis Asia Pacific, creating a regional powerhouse

Published

on

logicalis-unites-australia-and-asia-operations-as-logicalis-asia-pacific,-creating-a-regional-powerhouse

LONDON, May 9, 2024 /PRNewswire/ — Logicalis, a leading global technology services provider, has announced the creation of a new Asia Pacific entity, combining its Logicalis Australia and Logicalis Asia operations. This strategic realignment will be effective from June 01, 2024, and positions Logicalis to amplify its market presence through increased synergy within the APAC region.

The combined Logicalis Asia Pacific entity will consolidate 1,600 employees with a collective revenue upwards of $US350 million across 10 countries, including Singapore, Malaysia, Hong Kong, China, Thailand, Indonesia, Taiwan, Philippines, Vietnam, and now Australia. The newly formed entity will be led by Chong-Win Lee as the Chief Executive Officer (CEO) of Logicalis Asia Pacific with Anthony Woodward continuing in his role as CEO of Logicalis Australia and reporting to Chong-Win Lee. In addition to his current responsibilities, Woodward will lead a special task force focused on fostering innovation and identifying synergistic, joint opportunities across the region.
Chong-Win Lee, CEO, Logicalis APAC, said, “The strategic consolidation of Logicalis’ operations across Australia and Asia marks a pivotal moment in the company’s continued growth and evolution. The aim of this reorganisation is to build a powerhouse capable of delivering high-impact technology solutions more efficiently for customers across Asia Pacific, while still providing the local expertise and support that Logicalis customers value.”
The combination is designed to enhance service delivery and bring a cohesive solution portfolio to customers, reflecting the alignment of Logicalis Asia’s strategy to enable XaaS operating models to support digital transformation, and Logicalis Australia’s commitment to becoming the best MSP in the country. The combined operation will deliver seamless access to Logicalis’ experience in industry sectors such as financial services, government and healthcare, empowering teams to build skill and capacity for data and application modernisation, cloud managed services, artificial intelligence (AI), and more. From a security perspective, it will reinforce the company’s powerful customer proposition, giving customers access to the global network of threat intelligence research and experience encapsulated in the regional Logicalis Security Operations Centre (SOC).
Anthony Woodward, CEO, Logicalis Australia, said, “Formally combining the strengths of Logicalis Australia and its Asia counterparts is an acceleration of what has already been happening organically. This evolution lets Logicalis Australia and our customers leverage high-value digital capabilities from across the region, ensuring faster, more competitive, and more comprehensive service offerings. It also strengthens the local team’s onshore capabilities while integrating best practices and expertise from across Asia, enabling the delivery of scalable, cost-effective managed service options for customers.”
The announcement comes at a time when Logicalis has been increasingly focusing on expanding its core Microsoft and Cisco businesses, enhancing its capabilities in cloud, cybersecurity, and managed services. Logicalis Asia has also recently brought Atlassian onboard as a strategic vendor. Chong-Win Lee, CEO, Logicalis Asia Pacific, said, “The Logicalis Asia Pacific entity will help the company to achieve greater influence with vendors and deliver even greater outcomes for customers into the future.”
Bob Bailkoski, global CEO, Logicalis said, “The goal for Logicalis is clear: to harness the collective strengths of the company’s diverse operations to drive innovation and growth throughout Australia, Asia, and the globe. This reorganisation represents a strategic response to the evolving IT landscape and reinforces Logicalis’ commitment to developing solutions that support its customers’ success in the digital age.”
About Logicalis 
We are Architects of Change™. We help organisations succeed in a digital-first world. At Logicalis, we harness our collective technology expertise to help our clients build a blueprint for success, so they can deliver sustainable outcomes that matter.
Our lifecycle services across cloud, connectivity, collaboration, and security are designed to help optimise operations, reduce risk and empower employees.
As a global technology service provider, we deliver next-generation digital managed services, to provide our clients with real-time visibility and actionable insights across the performance of their digital ecosystem including; availability, user experience, security, economic performance and sustainability.
Our 7000+ ‘Architects of Change’ are based in 30 territories around the globe, helping our 10,000+ clients across a range of industry sectors create sustainable outcomes through technology.
Logicalis has annualised revenues of $1.7 billion, from operations in Europe, North America, Latin America, Asia Pacific, and Africa.
It is a division of Datatec Limited, listed on the Johannesburg Stock Exchange, with revenues of over $5.1 billion.
For more information visit https://www.logicalis.com
For media enquiries, contact:
Logicalis Team at Another Word 
Email: [email protected]
Tel: 020 3176 0014
 
 

View original content:https://www.prnewswire.co.uk/news-releases/logicalis-unites-australia-and-asia-operations-as-logicalis-asia-pacific-creating-a-regional-powerhouse-302141050.html

Continue Reading

Artificial Intelligence

Raiinmaker to make a splash on Yield App Angel Launchpad

Published

on

raiinmaker-to-make-a-splash-on-yield-app-angel-launchpad

ROME, May 9, 2024 /PRNewswire/ — Raiinmaker, a Web3 and AI Technology company that has developed the Raiinmaker AI Super App and Raiinmaker Network is revolutionizing the monetization of users’ contribution to AI infrastructure. Today, Yield App proudly announced that an exclusive $200,000 allocation of Raiinmaker’s native token, $COIIN, will be the second-ever offering on its Angel Launchpad!

Established in 2018, Raiinmaker is on a mission to empower anyone with a smartphone anywhere in the world, to earn cryptocurrency through training AI models and running an independent validator node. By leveraging groundbreaking Web3 and AI technology, Raiinmaker provides a decentralized platform for AI developers and validators to collaborate securely and exchange AI models.
Validators on Raiinmaker earn rewards for their contributions, fostering a culture of active engagement and top-tier performance. The platform operates on a transparent governance framework, allowing community members to play a pivotal role in decision-making processes.
Raiinmaker’s token and platform are designed with interoperability in mind, ensuring seamless integration with major blockchain networks. The Raiinmaker Network Protocol harnesses decentralized AI and scalable Web3 infrastructure to redefine the value associated with identity, data, and behavior. Built on this network, Raiinmaker’s Super App is set to transform how users monetize their contributions to AI infrastructure via the platform’s native token, $COIIN.
Raiinmaker’s team is composed of industry veterans from corporate giants such as Disney, Oracle and Boeing. With a wealth of experience and a shared passion for innovation, this team is driving Raiinmaker’s mission to revolutionize the digital landscape.
“We’re excited to be the second project with our native token, $COIIN, as an offering on the Yield App Angel Launchpad and we share the same vision of providing investment opportunities for crypto enthusiasts,” said J.D. Seraphine, Founder and CEO of Raiinmaker.
Raiinmaker’s $COIIN token will be offered on the Yield App Angel Launchpad on 9 May 2024. To prepare for launch day, Yield App users can ensure they have a positive USDT balance in their Yield App wallet. This will be used for token allocation during the pledge period.
Before making their pledge, Yield App users must also have Gold tier, Diamond tier, or Angel status. This can be achieved by staking YLD on the Yield App platform. For more details on YLD and the loyalty program, visit the YLD page on Yield App’s website.
With Angel status, users enjoy exclusive benefits such as guaranteed minimum allocation on each Launchpad launch and no maximum pledge cap. Plus, Angel status includes all the benefits of Diamond tier, including top rates on all products. Users can now unlock unlimited access to Angel Launchpad by buying Lifetime Angel status with a one-time fee of 50,000 YLD or by staking 100,000 YLD.
During the pledge period, participants will need to submit a Base Protocol (BASE) address to receive their token allocation, paving the way for a seamless user experience.
“We are thrilled to welcome Raiinmaker and their innovative $COIIN token to the Yield App Angel Launchpad,” said Tim Frost, CEO of Yield App. “Our second Launchpad offering aligns with our vision of empowering users in the digital asset space, and opens up an exciting opportunity for our users with Gold tier, Diamond tier, or Angel status.”
For more updates on the official offering of $COIIN token, visit the Yield App Angel Launchpad website.
About Raiinmaker
Raiinmaker is a Web3 and AI Technology Company that has developed the Raiinmaker AI Super App and Raiinmaker Network Protocol, which revolutionizes the monetization of users’ contribution to AI infrastructure.
About Yield App
Yield App is a digital wealth platform that serves as a digital wealth partner to its customers. The company’s mission is to provide safe custody for digital assets and enable users to exchange and earn at market-leading rates. Yield App achieves this through its innovative technology that seamlessly bridges traditional and decentralized finance, offering users a more efficient and user-friendly way to manage their portfolios.
Photo – https://mma.prnewswire.com/media/2407560/Raiinmaker_x_Angel_Launchpad_1280x720.jpg
Logo – https://mma.prnewswire.com/media/2407862/Logo_Horizontal_Colours_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/raiinmaker-to-make-a-splash-on-yield-app-angel-launchpad-302140022.html

Continue Reading

Trending